The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy
Ken Fujioka(Scripps Clinic), Frank L. Greenway(Pennington Biomedical Research Center), Kye Gilder(VistaGen Therapeutics (United States)), Raymond A Plodkowski(Scripps Clinic), Patrick M. O’Neil(Medical University of South Carolina), Brandon Walsh(VistaGen Therapeutics (United States))
Cited by 85
Related Papers
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
|New England Journal of Medicine|2015|2.6k
American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity
|Endocrine Practice|2016|1.8k
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2010|1k
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
|The Lancet|2017|843
Vitamin D Supplementation and Prevention of Type 2 Diabetes
|New England Journal of Medicine|2019|662